Disappearance of B-Symptoms In Comorbid Patients Receiving First-Line Obinutuzumab (Ga101) -Chlorambucil (G-Clb) Or Rituximab-Chlorambucil (R-Clb) for Chronic Lymphocytic Leukemia (Cll)
Abstract
Authors
Andres S. Wenk U. Becker S. Klawitter C. Wiesner A. Bernhardt